SRR1797228
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.560
- E2F_TARGETS+0.260
- WNT_BETA_CATENIN_SIGNALING+0.170
- DNA_REPAIR+0.140
- MITOTIC_SPINDLE+0.140
- G2M_CHECKPOINT+0.100
- GLYCOLYSIS+0.070
- PI3K_AKT_MTOR_SIGNALING+0.070
- UNFOLDED_PROTEIN_RESPONSE+0.070
- NOTCH_SIGNALING+0.060
Top 10 suppressed
- ANGIOGENESIS-0.540
- ALLOGRAFT_REJECTION-0.470
- INFLAMMATORY_RESPONSE-0.450
- INTERFERON_ALPHA_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- INTERFERON_GAMMA_RESPONSE-0.410
- COAGULATION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- APOPTOSIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 80680b8f-eec8-4b02-95c4-f133af61943a | — | — | 0.828 |
| 2 | MDT-AP-1339 | Med | Medulloblastoma | 0.826 |
| 3 | SRR13780269 | — | cohortSC | 0.825 |
| 4 | MDT-AP-0511 | Med | Medulloblastoma | 0.823 |
| 5 | TCGA-BH-A0HL-01A-11R-A10U-07 | — | B | 0.823 |
| 6 | sclc2008_S40.txt | — | cohortSC | 0.822 |
| 7 | MDT-AP-0382 | Med | Medulloblastoma | 0.820 |
| 8 | SRR1797255 | — | cohortSC | 0.820 |
| 9 | SRR6013576 | — | cohortMD1 | 0.819 |
| 10 | TCGA-GV-A3QI-01A-11R-A220-07 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.560 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |